Carefully Selected Quotes,
by Ye Editor
"CONCLUSION:
"Mainstream media sources such as The Wall Street Journal continue to publish unbalanced and poorly researched articles while enormous stories are unfolding behind the wall of corporate-funded propaganda.
Dr. Andrew Hill’s own opinion, when untrammeled by hidden influence, suggested 75% of COVID deaths could have been prevented by using ivermectin as treatment.
The “hidden hands” of profit-driven operatives are taking an enormous toll on humanity through their manipulation of public and scientific opinion.
In the end, the public must decide when enough is finally enough.
DETAILS:
... "The Wall Street Journal on March 18 published an article with this headline: “Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date.”
Headline readers will easily reach the seemingly obvious conclusion: Drs. Anthony Fauci and Rochelle Walensky, along with the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention, were right all along.
... “The latest trial, of nearly 1,400 Covid-19 patients at risk of severe disease, is the largest to show that those who received ivermectin as a treatment didn’t fare better than those who received a placebo.”
This was not the largest trial to date — it was only the largest trial to date among the subset of trials that have shown no benefit of ivermectin.
... was (this) a deliberate attempt to confuse the 42 million readers of The Wall Street Journal’s digital content?
... it is impossible for a study to definitively prove that no effect exists. This is what is referred to in science as the null hypothesis, meaning an intervention has no effect.
It is entirely possible that a study may demonstrate no measurable effect. It is quite a different thing to prove that that same intervention will not have an effect under any circumstances. To put it flatly, one cannot prove that something doesn’t exist.
The author chose not to mention the 81 separate studies — involving a combined 128,000 participants — that demonstrated an average efficacy of 65% for several different outcomes. https://ivmmeta.com/
She also did not mention the 22 studies — involving nearly 40,000 people — around the outcome in question, hospitalization. Those studies showed an average efficacy of 39%.
The Wall Street Journal did not cite the study that was the focus of its article, because the study hasn’t yet been published. ... With no paper to cite, the journal instead quoted Edward Mills, one of the study’s lead researchers and a professor of health sciences at Canada’s McMaster University in Hamilton, Ontario: “There was no indication that ivermectin is clinically useful.”
... The Wall Street Journal article is yet another widely read piece that cherry-picks studies that purportedly show no benefit while categorically ignoring the mounting evidence to the contrary.
The systematic suppression of ivermectin’s efficacy against COVID has been well documented by The Defender here, and in Robert F. Kennedy, Jr.’s New York Times bestselling book, “The Real Anthony Fauci.”
... Dr. Tess Lawrie, director of The Evidence-Based Medicine Consultancy, Ltd. and other researchers were collaborating to publish their findings in early 2021. Those findings would definitively conclude that ivermectin could and should be used to treat COVID at all stages of the disease.
On Jan. 18, 2021, days before the planned publication of this joint effort, Hill chose to independently release his findings on preprint servers. He concluded the opposite of what he and others had found through their research:
“Ivermectin should be validated in larger appropriately controlled randomized trials before the results are sufficient for review by regulatory authorities.”
... When Lawrie confronted a squirming Hill, Hill eventually admitted the conclusions in his analysis had been influenced by Unitaid, a quasi-governmental advocacy organization funded by the Bill & Melinda Gates Foundation and several countries
— France, the UK, Norway, Brazil, Spain, the Republic of Korea and Chile — to lobby governments to finance the purchase of medicines from pharmaceutical multinationals for distribution to the African poor.
As Kennedy, chairman and chief legal counsel for Children’s Health Defense, writes in his book: “Unitaid gave $40 million to Andrew Hill’s employer, the University of Liverpool, four days before the publication of Hill’s study. Hill, a Ph.D., confessed that the sponsors were pressuring him to influence his conclusion.
“When Dr. Lawrie asked who was trying to influence him, Hill said, ‘I mean, I, I think I’m in a very sensitive position here …’” Who was the Unitaid member who impelled Hill to change his tune?
Thanks to the sleuthing by Phil Harper, producer, director and author of a Substack newsletter under the moniker “The Digger,” we may have an answer. ... (in a) Substack article, Harper explained how he was able to identify crucial changes made in the days prior to the study’s distribution by comparing it to a previous version that was emailed to Lawrie. This original version was not made public.
The changes were subtle but clearly designed to weaken the conclusions of the analysis. Even more suspicious was the deletion of Unitaid’s financial contribution in the form of an “unrestricted research grant” from the funding declaration portion of the paper.
By examining the metadata attached to the PDF document Hill submitted to several preprint servers, Harper discovered that the author (as indicated in the metadata) of the paper was Andrew Owen, a professor of pharmacology & therapeutics and co-director of the Centre of Excellence in Long-acting Therapeutics (CELT) at the University of Liverpool.
Harper continues: “His authorship is tied programmatically to the document, meaning a device or software programme registered to the name Andrew Owen saved off the document as a PDF. When exporting a PDF, Microsoft Word automatically adds title and author information.
“Unless someone used his computer, Andrew Owen has his digital fingerprint on the Andrew Hill paper. A paper we have very strong reason to believe was altered by ‘people’ at Unitaid.”
Owen is also a scientific advisor to the WHO’s COVID-19 Guideline Development Group. Just days before Hill’s original paper was to be published, a $40 million grant from Unitaid, the paper’s sponsor, was given to CELT. Owen is the project lead for that grant.
According to Harper: “The $40 million contract was actually a commercial agreement between Unitaid, the University of Liverpool and Tandem Nano Ltd (a start-up company that commercializes ‘Solid Lipid Nanoparticle’ delivery mechanisms) — for which Andrew Owen is a top shareholder.”
Owen is not listed as an author of the analysis, yet his digital fingerprint is on its last-minute revisions. Instead, Hill listed all the authors of the studies that his systematic review was critiquing as co-authors of the review itself. This is a striking departure from standards of a systematic review, as it undermines the purpose and objectivity of such an analysis."
